Vycellix, Avectas partner for product development

By The Science Advisory Board staff writers

March 26, 2020 -- Vycellix and Avectas have unveiled plans to collaborate on the development of cell-based immunotherapeutic products.

The companies will partner on the use of Vycellix's RNA immunomodulator VY-M for immunodiscovery cell and gene therapy with Avectas' Solupore cell engineering platform to address the current limitations of cell-based therapies and the need to accelerate manufacturing processes, reduce manufacturing costs, and improve patient outcomes.

Vycellix and Avectas also are currently collaborating with NextGenNK, a newly established competence center for the development of next-generation natural killer cell-based cancer immunotherapies based at Karolinska Institutet in Stockholm, Sweden.


Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
2nd Annual Cell Therapy Bioprocessing Conference
June 25-26
Boston, Massachusetts United States
BioProcess International Europe
July 13-16
Amsterdam, Noord-Holland Netherlands
Bioprocess International West
August 10-13
Santa Clara, California United States
BioProcess International
September 21-24
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter